Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (TSE:DTC)
:DTC
Total Valuation
Defence Therapeutics has a market cap or net worth of C$33.93M. The enterprise value is C$36.22M.
Market CapC$33.93M
Enterprise ValueC$36.22M
Share Statistics
Defence Therapeutics has 54,725,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,725,370
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Defence Therapeutics’s return on equity (ROE) is 2.80 and return on invested capital (ROIC) is -1315.83%.
Return on Equity (ROE)2.80
Return on Assets (ROA)-2.13
Return on Invested Capital (ROIC)-1315.83%
Return on Capital Employed (ROCE)2.60
Revenue Per Employee0.00
Profits Per Employee-704.41K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Defence Therapeutics is ―. Defence Therapeutics’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio-27.77
Price to Fair Value-27.77
Price to FCF-10.26
Price to Operating Cash Flow-8.45
PEG Ratio0.13
Income Statement
In the last 12 months, Defence Therapeutics had revenue of 0.00 and earned -3.52M in profits. Earnings per share was -0.07.
Revenue0.00
Gross Profit-72.34K
Operating Income-3.27M
Pretax Income-3.52M
Net Income-3.52M
EBITDA-3.13M
Earnings Per Share (EPS)-0.07
Cash Flow
In the last 12 months, operating cash flow was -4.94M and capital expenditures 808.28K, giving a free cash flow of -4.13M billion.
Operating Cash Flow-4.94M
Free Cash Flow-4.13M
Free Cash Flow per Share-0.08
Dividends & Yields
Defence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change-43.48%
50-Day Moving Average0.67
200-Day Moving Average0.74
Relative Strength Index (RSI)53.89
Average Volume (3m)68.27K
Important Dates
Defence Therapeutics upcoming earnings date is May 22, 2026, After Close (Confirmed).
Last Earnings DateFeb 20, 2026
Next Earnings DateMay 22, 2026
Ex-Dividend Date―
Financial Position
Defence Therapeutics as a current ratio of 0.50, with Debt / Equity ratio of -211.09%
Current Ratio0.50
Quick Ratio0.50
Debt to Market Cap0.04
Net Debt to EBITDA-0.09
Interest Coverage Ratio-10.14
Taxes
In the past 12 months, Defence Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Defence Therapeutics EV to EBITDA ratio is -11.24, with an EV/FCF ratio of -10.34.
EV to Sales0.00
EV to EBITDA-11.24
EV to Free Cash Flow-10.34
EV to Operating Cash Flow-10.34
Balance Sheet
Defence Therapeutics has C$947.35K in cash and marketable securities with C$1.49M in debt, giving a net cash position of -C$540.37K billion.
Cash & Marketable SecuritiesC$947.35K
Total DebtC$1.49M
Net Cash-C$540.37K
Net Cash Per Share>-C$0.01
Tangible Book Value Per Share-C$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Defence Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast72.92%